About AVDL

Flamel Technologies SA (NASDAQ: FLML) is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs.Flamel currently has approvals for and markets two previously Unapproved Marketed Drugs ("UMDs") in the USA, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection).The Company intends to add to this branded business by creating additional products, focusing on the development of products utilizing Flamel's proprietary drug delivery platforms, and recently announced FDA acceptance of its third NDA filing with an FDA-assigned PDUFA date of April 30, 2016.Flamel also has several products in development utilizing Micropump (oral sustained release microparticles platform) along with its tangent technologies, LiquiTime and Trigger Lock.The lead project for Micropump is sodium oxybate. LiquiTime allows for the extended-release of liquid medicines (such as ibuprofen and guaifenesin) and Trigger Lock is an abuse-resistant iteration of Micropump, designed specifically for long-acting opioids (such as hydromorphone).Additionally, the Company has developed a long acting injectable platform, Medusa, a hydrogel depot technology currently being studied with exenatide.Flamel's products are targeting high-value molecules and will utilize either the 505(b)(2) approval process for NDAs or biosimilar pathways ultimately approved by FDA and other regulatory authorities. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and Dublin, Ireland.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

Wait, Before You Leave...